LA JOLLA, Calif., March 11, 2020 -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system.

INmune Bio, Inc. (INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced today the publication of new positive data in the journal Alzheimer’s Research & Therapy. The data highlights INmune Bio’s lead compound, XPro1595, as a potentially effective therapy to lower the risk for Alzheimer’s disease in obese individuals.

INmune Bio’s CEO, Dr. R.J. Tesi, will moderate a panel of experts from neuroscience research, clinical trials, and Alzheimer’s drug development. Lawrence T. Friedhoff, M.D., Ph.D., who is credited with the development and commercialization of Aricept, which was FDA approved for the symptomatic treatment of mild to moderate Alzheimer's disease.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

LA JOLLA, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced today the dosing of the first patient in the Phase Ib clinical trial for patients with Alzheimer's disease. The trial is examining the safety and efficacy of INmune Bio’s XPro1595, a next-generation anti-inflammatory drug that selectively neutralizes the “bad” inflammation, soluble tumor necrosis factor (sTNF), which is strongly implicated in Alzheimer's disease.

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

INmune Bio, Inc. (INMB) (the “Company”), a clinical-stage immunology company focused on  developing treatments that harness the patient’s innate immune system to fight disease, announced publication of a review article:   Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer in the journal Stem Cells Translational Medicine by May Sabry, PhD and Professor Mark Lowdell, PhD, co-founder and Chief Scientific Officer of INmune Bio, past vice-president (Europe) of the International Society of Cell & Gene Therapy (ISCT) and faculty professor at University College London. The article reviews the potential of harnessing cells of the innate immune system to treat cancer.

INmune Bio, Inc., an immunology company developing therapies that reprogram the patient’s innate immune system to treat diseases, today announced that it has successfully completed the Phase I trial of INB03 and the database has been locked. The Phase I trial was an open-label, dose-escalation trial in patients with advanced solid tumors. “This was our first trial of the DN-TNF platform in patients, and we are pleased with the safety and efficacy results,” said RJ Tesi, MD, CEO and CMO of INmune Bio.

INmune Bio, Inc. (INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the United States Patent and Trademark Office (USPTO) has given formal notice of allowance in patent application serial no. 15/268,399, titled “IN VIVO PRIMING OF NATURAL KILLER CELLS,” which covers a method of treating cancer by administering a proprietary inactivated cellular material preparation and contacting a patient’s own natural killer cells within the body to induce an in vivo response, namely, the priming of NK cells for enhancing innate immunity and the NK cell ability to recognize and kill cancer cells within the patient. The newly allowed patent is expected to issue within ninety days and will be set to expire in 2036, subject to patent term adjustment or extension.

INmune Bio, Inc. (INMB) (the “Company”), a clinical-stage immunology company focused on  developing treatments that harness the patient’s innate immune system to fight disease, announced presentation of a study  demonstrating the combination of INB03 with lapatinib reverses resistance to therapy in trastuzumab resistant HER2+ breast cancer. The work lays the groundwork for INmune Bio’s planned Phase II trial and, was chosen for an oral presentation at the New York Academy of Science Frontiers in Cancer Immunotherapy 2020 publication on Monday, 11 May.  Sophi Bruni, a doctoral student in the laboratory of Dr. Roxana Schillaci, in the Lab of Molecular Mechanisms, Instituto de Biología y Medicina Experimental-CONICET, Argentina will be presenting the work.

INmune Bio, Inc., an immunotherapy company developing therapies that reprogram the patient’s innate immune system to treat disease, today announced that it will release financial results for its 2019 fourth quarter and year end on Wednesday, March 11, 2020. The Company will hold a conference call at 11AM Eastern (U.S.) time on March 11, 2020. INmune Bio, Inc. is a publicly traded (INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system.

INmune Bio, Inc. (INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced publication of an invited review in Frontiers in Oncology: Tumor Necrosis Factor α Blockade: an Opportunity to Tackle Breast Cancer, by Dr. Roxana Schillaci, in the Lab of Molecular Mechanisms, Instituto de Biología y Medicina Experimental-CONICET, Argentina.

INmune Bio, Inc. (INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced the initiation of a therapeutic program to treat patients with pulmonary complications from COVID-19 infection with its dominant-negative TNF inhibitor (DN-TNF) platform. Management will host a conference call on April 20th, 2020 at 4:15 PM ET to discuss the science and strategy behind its DN-TNF platform and its decision to begin the new clinical trial.

INmune Bio, Inc. (INMB), an immunology company developing treatments that reprogram the patient’s innate immune system to fight disease, today announced that it has been awarded a $500,000 grant from The ALS Association. The grant will fund proof-of-concept studies for XPro1595, a novel therapy targeting innate immune dysfunction and chronic inflammation as a cause of Amyotrophic lateral sclerosis (ALS). The endowment was awarded through the Association’s The Lawrence and Isabel Barnett Drug Development Program and will be allocated over two years. “We are honored to receive this grant from The ALS Association, the pre-eminent organization supporting novel treatments for ALS,” said R.J. Tesi, M.D., Chief Executive Officer of INmune Bio.

By David Bautz, PhD NASDAQ:INMB READ THE FULL INMB RESEARCH REPORT Business Update Data from Phase 1 Trial of XPro1595 in Alzheimer’s Disease in 2H20 INmune Bio, Inc. (NASDAQ:INMB) is currently conducting a Phase 1 clinical trial of XPro1595 in patients with Alzheimer’s Disease (AD). The trial is supported by a $1 million grant from the Alzheimer’s Association, which is derived from the Part the

By David Bautz, PhD NASDAQ:INMB READ THE FULL INMB RESEARCH REPORT Business Update Testing DN-TNF Platform as Treatment for COVID-19 On April 20, 2020, INmune Bio, Inc. (NASDAQ:INMB) announced that the company will be testing the company’s dominant-negative tumor necrosis factor (DN-TNF) platform as a treatment for COVID-19 caused by the novel coronavirus SARS-CoV-2. The DN-TNF platform is based

LA JOLLA, Calif., May 14, 2020 -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system.

INmune Bio, Inc. (INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that it will host a conference call on May 14, 2020 at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2020. INmune Bio, Inc. is a publicly traded (INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.

INmune Bio, Inc., an immunology company developing treatments that harness the patient’s innate immune system to fight disease, today announced that management will present at the 32nd Annual Roth Conference at 8:30 a.m. (PT) on Tuesday, March 17, 2020 and will conduct one-on-one meetings that day. The conference will be held March 15-17, 2020 at The Ritz Carlton, Laguna Niguel in Orange County, CA. The ROTH Conference, with close to 550 participating companies and over 5,100 attendees, will feature presentations from public and private companies in a variety of sectors.

INmune Bio, Inc. (INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that RJ Tesi, MD, CEO and CMO of INmune Bio will participate on a COVID-19 therapeutics panel discussion, at Maxim Group’s Infectious Disease Virtual Conference at 3:45pm ET, on Tuesday, May 5, 2020. Dr. Tesi will discuss treating COVID-19 as an inflammatory disease.